



Ombudsman inquiry strengthens transparency and objectivity of EMA's assessment of new medicines

Case OI/7/2017/KR - **Opened on** 17/07/2017 - **Decision on** 17/07/2019 - **Institution concerned** European Medicines Agency (No further inquiries justified) |

26 November 2019 - An Ombudsman inquiry into how the **European Medicines Agency (EMA)** engages with pharma companies before they apply for market access for their medicines has led to several **measures to improve the transparency and objectivity of the process** .

Working constructively with the Ombudsman, [EMA has agreed \[Link\]](#) to introduce a **log of the scientific advice concerning medicines in the market approval process** . This advice will be made public once the medicine is allowed to be sold in Europe. EMA has also said that, to the greatest extent possible, the **experts that are prominently involved in advising pharmaceutical companies in the pre-market application phase will not be those that draft EMA's evaluation report for a new medicine** .